The tweet was deleted by the author.
But we saved everything 🙂.
Climb Bio, Inc. took part in a fireside chat hosted by HC Wainwright earlier today.
The session provided insights into the company’s ongoing initiatives and future direction, with a particular focus on advancements in immunology, autoimmune disorders, nephrology, and B-cell therapies. Interested parties can access a replay of the event to learn more about Climb Bio, Inc.’s strategic vision and upcoming milestones.
Climb Bio, Inc. previously joined an initiative focused on advancing patient-centered, scientifically rigorous IgA nephropathy clinical trials. The company also hosted a webcast with Dr. David Jayne to discuss budoprutug and anti-CD19 therapy opportunities. These activities reflect Climb Bio’s ongoing engagement in therapeutic development across immunology and nephrology.